DSC Advisors L.P. decreased its position in Amgen, Inc. (NASDAQ:AMGN) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,274 shares of the medical research company’s stock after selling 57 shares during the period. Amgen makes up approximately 1.3% of DSC Advisors L.P.’s investment portfolio, making the stock its 20th largest position. DSC Advisors L.P.’s holdings in Amgen were worth $2,233,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the company. Advantage Investment Management LLC purchased a new stake in Amgen during the fourth quarter worth $879,000. IFM Investors Pty Ltd purchased a new stake in Amgen during the fourth quarter worth $1,400,000. LeJeune Puetz Investment Counsel LLC purchased a new stake in Amgen during the fourth quarter worth $1,846,000. Independent Advisor Alliance purchased a new stake in Amgen during the fourth quarter worth $305,000. Finally, Sustainable Insight Capital Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $3,538,000. Institutional investors own 79.04% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) traded down 1.01% on Friday, hitting $160.41. 2,895,639 shares of the stock traded hands. Amgen, Inc. has a one year low of $133.64 and a one year high of $184.21. The company has a market cap of $118.13 billion, a PE ratio of 15.67 and a beta of 1.15. The stock has a 50 day moving average of $169.01 and a 200 day moving average of $158.67.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 2nd. The medical research company reported $2.89 EPS for the quarter, topping the consensus estimate of $2.79 by $0.10. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The business had revenue of $5.97 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period in the previous year, the firm earned $2.61 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Equities analysts anticipate that Amgen, Inc. will post $12.33 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Wednesday, May 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Monday, May 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.87%. Amgen’s dividend payout ratio is presently 44.92%.
Several analysts have commented on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $193.00 price objective on shares of Amgen in a report on Tuesday, March 14th. Jefferies Group LLC restated a “buy” rating and issued a $194.00 price objective (down from $198.00) on shares of Amgen in a report on Friday, February 3rd. Mizuho restated a “buy” rating on shares of Amgen in a report on Wednesday, February 8th. Argus set a $195.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Saturday, February 11th. Finally, BMO Capital Markets raised their price objective on shares of Amgen from $202.00 to $212.00 and gave the stock an “outperform” rating in a report on Monday, February 13th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and an average price target of $186.94.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.